The Hill: The main drug industry lobbying group on Tuesday said that it had "serious concerns" with major elements of President Trump's new plan to bring down drug prices.
In the first extended remarks on the plan since Trump unveiled it last Friday, Lori Reilly, an executive vice president of the Pharmaceutical Research and Manufacturers of America (PhRMA), pointed to several proposals she said would harm patient access to drugs.
Democrats and some other observers have criticized Trump's plan for not going far enough to take on drug companies. For example, the plan does not include a call for Medicare to negotiate drug prices directly.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now